Latest FDA Stories
Sports Nutrition Ingredient, Nitrosigine, Supplies Bodybuilding Expo with Bicep Pump Challenge Columbus, Ohio (PRWEB) March 04, 2015 Nitrosigine®,
The FDA is requiring the manufacturers of low testosterone therapy drugs to warn patients that the medications may increase the risk for heart attacks and strokes. New
FDA investigators generally know within four hours of an inspection whether a manufacturer’s in trouble or not.
NuMale Medical Center Founder and Chief Medical Officer Dr. Christopher Asandra, M.D.
- Initial Hepatoren® Phase II study results NASHVILLE, Tenn., March 3, 2015 /PRNewswire/ -- Cumberland Pharmaceuticals Inc.
HORSHOLM, Denmark, March 3, 2015 /PRNewswire/ -- Veloxis Pharmaceuticals A/S (OMX: VELO) ('Veloxis') today published the annual report of Veloxis Pharmaceuticals A/S for the financial year 2014.
FDA one step closer to final approval for sight saving treatment that could help hundreds of thousands across U.S. San Antonio eye surgeon Dr.
The San Diego based law firm with its national network of experienced lawyers comments on the FDA's Adverse Reaction changes to the anticoagulant's labeling, as well as the development
The decision by UnitedHealthCare to restrict laparoscopic or abdominal hysterectomies comes months after the FDA warned against the use of power morcellators in such procedures, as the devices
DALLAS, March 2, 2015 /PRNewswire/ -- ReportsnReports.com adds Lonsurf and Avastin (Colorectal Cancer) - Forecast and Market Analysis to 2023 research report focuses on
- In medieval musical notation, a sign or neume denoting a shake or trill.